Search Results

You are looking at 111 - 120 of 800 items for :

  • "metastases" x
  • Refine by Access: All x
Clear All
Full access

Giuseppe Curigliano

Boston, MA, U.S.A.; Tuesday, 9.40 a.m. Patient: “Doctor, I am very worried about the CT scan report. It says ‘disease progression.’ ‘Progression’ means I have metastases, doesn’t it? How long will I live?” Milan, Italy; Tuesday, 11.00 a

Full access

Jennifer Shih, Babar Bashir, Karen S. Gustafson, Mark Andrake, Roland L. Dunbrack, Lori J. Goldstein, and Yanis Boumber

2 ). Based on the morphology and immunohistochemical profile, a lung primary was favored. A staging PET/CT confirmed the CT findings of at least stage IIIb disease. A brain MRI unfortunately showed 2 small cerebral metastases in the right and left

Full access

Owen Tan, Deborah J. Schofield, and Rupendra Shrestha

from a combination of pathology reports, inpatient notifications, and other treatment facilities. The variable was categorized as localized to tissue of origin, regional spread, adjacent organs and/or regional lymph nodes, distant metastases, and

Full access

Fei Gao, Nan Li, YongMei Xu, and GuoWang Yang

-related mortality and can have a harmful effect on these patients, and was associated with a significant decrease in survival. For patients with <6 positive lymph node metastases who did not receive POCT, however, RT can improve survival time, and for patients with

Full access

Vinayak Muralidhar, Paul L. Nguyen, Brandon A. Mahal, David D. Yang, Kent W. Mouw, Brent S. Rose, Clair J. Beard, Jason A. Efstathiou, Neil E. Martin, Martin T. King, and Peter F. Orio III

), and presence of distant metastases (M0 vs M1). Presence of nodal or distant metastases is recorded in the NCDB before treatment based on coding from patient medical records. The PSA cutoff of ≥98.0 ng/mL was chosen due to limitations in the NCDB: all

Full access

Quisette P. Janssen, Jacob L. van Dam, Laura R. Prakash, Deesje Doppenberg, Christopher H. Crane, Casper H.J. van Eijck, Susannah G. Ellsworth, William R. Jarnagin, Eileen M. O’Reilly, Alessandro Paniccia, Marsha Reyngold, Marc G. Besselink, Matthew H.G. Katz, Ching-Wei D. Tzeng, Amer H. Zureikat, Bas Groot Koerkamp, Alice C. Wei, and for the Trans-Atlantic Pancreatic Surgery (TAPS) Consortium

, a patient who undergoes a resection might be diagnosed with liver metastases 3 months after surgery; in the RT group, the same patient would be diagnosed with liver metastases at restaging after RT and would therefore not end up in the resection

Full access

Matthew D. Galsky, Harry W. Herr, and Dean F. Bajorin

Despite surgery with curative intent, approximately 50% of patients with muscle-invasive transitional cell carcinoma of the bladder will develop distant metastases and succumb to their disease. Attempts to improve outcomes have focused on refining surgical techniques and integrating perioperative chemotherapy. This review summarizes the available literature addressing the role of pelvic lymphadenectomy, neoadjuvant chemotherapy, and adjuvant chemotherapy in the management of patients with muscle-invasive transitional cell carcinoma of bladder.

Full access

Jason Hu, Armen G. Aprikian, Marie Vanhuyse, and Alice Dragomir

-month period before ADT initiation. 37 Metastatic status was also defined from the 18-month period before ADT initiation as the presence of an ICD code related to metastases or use of a metastatic castration-resistant PCa drug (ICD-9 was used for the

Full access

The UNMC Eppley Cancer Center at The Nebraska Medical Center

An estimated 38,890 Americans will be diagnosed with kidney cancer and 12,840 will die of this disease in the United States in 2006. Renal cell carcinoma (RCC) constitutes approximately 2% of all malignancies, with a median age at diagnosis of 65 years. Smoking and obesity are among the risk factors for RCC development, and tumor grade, local extent of the tumor, presence of regional nodal metastases, and evidence of metastatic disease at presentation are the most important prognostic determinants of 5-year survival. These guidelines discuss evaluation, staging, treatment, and management after treatment.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Small cell lung cancer (SCLC) accounts for 15% to 25% of all lung cancers. About 98% of SCLC is attributed to cigarette smoking, whereas the remaining cases are presumably caused by environmental or genetic factors. In 2003, an estimated 34,000 new cases of SCLC will have been diagnosed in the United States. SCLC is distinguished from non-small cell lung cancer by its rapid doubling time, high growth fraction, and early development of widespread metastases.

For the most recent version of the guidelines, please visit NCCN.org